论文部分内容阅读
目的:探讨黄连解毒汤(HLJDT)对慢性粒细胞白血病(CML)加速期的治疗作用,以及HLJDT及其主要活性成份之一的黄芩素对血红素加氧酶-1(HO-1)表达的影响。方法:通过对1例CML的患者口服HLJDT治疗6个月的观察,外周血检查和骨髓穿刺分析治疗前后外周血象和骨髓象的变化;流式细胞术分析HLJDT和黄芩素对CML细胞系K562的活细胞计数的影响;逆转录多聚酶链反应(RT-PCR)检测患者骨髓单个核细胞HO-1基因的表达;蛋白印记检测经黄芩素处理后K562细胞HO-1蛋白的表达水平。结果:口服HLJDT对CML加速期的治疗有效,可明显降低骨髓和外周血原始粒细胞和早幼粒细胞数,使疾病重新回复到慢性期;并且在体内能降低肿瘤细胞HO-1基因的表达,在体外,HLJDT能抑制K562细胞的增殖,且其主要成份黄芩素亦有相同作用,并且下调HO-1蛋白的表达。结论:HLJDT具有治疗CML加速期的作用,其机理与抑制HO-1基因和蛋白的表达有关;因此,HLJDT具有潜在的临床应用价值。
Objective: To investigate the therapeutic effect of Huanglian Jiedu Decoction (HLJDT) on the accelerated phase of chronic myeloid leukemia (CML) and the effect of baicalein on the expression of heme oxygenase-1 (HO-1), one of HLJDT and one of its main active ingredients influences. Methods: The changes of peripheral blood and bone marrow before and after treatment of peripheral blood and bone marrow aspiration were observed in 6 patients with HLMDT treated by oral HLJDT in one patient with CML. Flow cytometry was used to analyze the effect of HLJDT and baicalein on the expression of CML cell line K562 The expression of HO-1 gene in bone marrow mononuclear cells was detected by reverse transcription polymerase chain reaction (RT-PCR). The protein expression of HO-1 in K562 cells treated with baicalein was detected by Western blotting. Results: Oral administration of HLJDT can effectively reduce the expression of HO-1 in tumor cells in the accelerated phase of CML, and significantly reduce the numbers of myeloblast and promyelocytic cells in the bone marrow and peripheral blood, so that the disease regains the chronic phase. In vitro, HLJDT can inhibit the proliferation of K562 cells, and the main component of baicalein also has the same effect, and down-regulates the expression of HO-1 protein. CONCLUSION: HLJDT has the effect of accelerating CML. Its mechanism is related to the inhibition of HO-1 gene and protein expression. Therefore, HLJDT has potential clinical value.